H eart morphogenesis is a complex process that involves orchestration of cardiac cell commitment, differentiation, proliferation, and migration. Much progress has been made toward understanding the molecular mechanisms that regulate these events during normal development. However, the role of chromatin modification for heart development has received comparatively little attention, despite the fact that epigenetic modifications establish a cell-type-specific chromatin pattern that is of paramount importance for cell commitment and differentiation.
The polycomb group proteins are key regulators of gene expression during development and differentiation, silencing genes via regulation of the chromatin structure ( Figure) . Polycomb group proteins act in complexes that have specific catalytic functions important for transcriptional repression. In mammals, 2 major Polycomb group complexes exist: Polycomb repressive complex 1 (PRC1) and 2 (PRC2). Whereas PRC1 ubiquitylates histone H2A on Lys119, 1 PRC2 catalyzes the dimethylation and trimethylation of H3 on Lys27, generating H3K27me2/3. 2 Generally, the H3K27me2/3 mark is specifically recognized by the chromodomain of Polycomb (Pc), a subunit of PRC1 complexes, 1 which provides a platform for PRC1 recruitment and Polycomb-mediated transcriptional repression. EZH1/2, SUZ12, and EED are core components of the PRC2 complex. The catalytic function of PRC2 requires either EZH1 or EZH2, both of which possess histone lysine methyltransferase activities. EZH1-and EZH2-containing complexes share an overlapping set of target genes, which suggests that they might have partially redundant functions. 3, 4 However, recent evidence suggests that EZH1 might catalyze trimethylation of H3 on Lys4, generating the active epigenetic mark H3K4me3, which calls into question the concept of redundancy between Ezh1 and Ezh2. 5 In vitro, EZH2 has a higher catalytic activity than EZH1 with respect to H4K27 trimethylation, but PRC2-EZH1 more effectively induces chromatin compaction and represses transcription. 3 Moreover, the 2 homologues have distinct spatial and temporal expression patterns, with EZH1 being more ubiquitously expressed and more abundant in adult organs, 3 which suggests that the 2 complexes may have both common and distinct functions. 3, 4 In the current issue of Circulation Research, He and colleagues 6 analyze the role of PRC2 in heart development. Previous studies have demonstrated the essential role of PRC2 during early embryonic development, because mice deficient for the core components of the complex display early embryonic lethality at embryonic day 7.5 through 8.5. [7] [8] [9] To study the role of PRC2 in heart development, He et al 6 conditionally inactivated Ezh2 using 2 different Cre lines: Nkx2-5:Cre, which is active in cardiac progenitors and cardiomyocytes, and TnT:Cre, active only in cardiomyocytes. Interestingly, inactivation of Ezh2 by Nkx2-5:Cre (Ezh2 NK ) led to embryonic lethality and congenital heart defects, including compact myocardial hypoplasia, hypertrabeculation, and ventricular and atrial septal defects, whereas inactivation of Ezh2 with TnT:Cre (Ezh2 TNT ) did not show an overt phenotype despite a modest upregulation of some target genes ( Figure) . The absence of an overt phenotype in Ezh2 TNT mice was attributed to redundant functions of Ezh1 and Ezh2, because inactivation of the nonredundant PRC2 component Eed by TnT:Cre led to embryonic lethality and heart defects, including compact myocardial hypoplasia. However, Eed TNT embryos did not show septal defects, which implies that the PRC2-EZH2 complex has distinct functions in regulating the chromatin state of cardiac progenitor cells. Using genome-wide RNA expression profiling of wild-type and Ezh2
NK -deficient hearts combined with chromatin immunoprecipitation, He et al 6 identified genes directly repressed by EZH2, including cell cycle regulators, transcriptional regulators of different developmental programs, and molecules important for cardiomyocyte function. 6 PRC2 regulates a number of these genes in other cell types, which suggests a common mode of action by which PRC2 regulates cellular decisions. 10, 11 Potentially most important for the decreased cardiomyocyte proliferation in Ezh2 NK hearts is the observed upregulation of the cell cycle inhibitors Ink4a (p16) and Ink4b (p15). Comparative expression analysis of Ezh2 TNT hearts, which did not show an overt phenotype, with malformed Eed TNT and Ezh2 NK hearts revealed that derepression of Ink4a/b, Isl1, and Pax6 is closely correlated with the phenotype. In contrast, upregulation of Six1 (which is highly expressed in cardiac progenitor cells but not in cardiomyocytes) was observed in both Ezh2 NK and Ezh2 TNT hearts, which indicates that it is not sufficient to cause congenital heart defects. Furthermore, PRC-EZH2 was also required for correct spatiotemporal regulation of typical cardiac genes such as Hcn4, Mlc2a, and Bmp10. Intriguingly, the derepression of key regulatory genes of different cell lineages (such as Pax6) observed in the mutant mice was not sufficient to divert
The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.the fate of cardiomyocytes, which corresponds to similar results in other cell types. 11 It is also interesting that only a small percentage of genes bound by Ezh2 and enriched for the H3K27Me3 repressive mark were differentially expressed, which highlights the existence of additional mechanisms to ensure proper gene repression and lineage commitment.
Further chromatin immunoprecipitation experiments in Ezh2
NK hearts for H3K27Me3 and other chromatin marks might provide additional insights into this phenomenon.
The possibility that PRC2 induces epigenetic changes in cardiac progenitor cells that become manifest only at later stages of heart development (ie, epigenetic memory) is fascinating, but the precise mechanisms remain unknown (Figure) . Most likely, the presence of additional factors such as the PRC1 complex, which also plays a crucial role in heart development, 12 is important for PRC2-mediated transcriptional repression at different stages of cardiogenesis. Proteomic approaches might be useful to identify cell-typespecific interaction partners of EZH2, which help to recruit EZH2 to specific chromatin regions and modulate its function during heart development. In fact, recent studies reported the association of the Jumonji C-containing protein JARID2 with PRC2. 13 It is assumed that localization of PRC2 to its respective target sites depends largely on JARID2 14 and that JARID2 acts both as an activator 15 and as an inhibitor 13 of PRC2-dependent H3K27 methylation. Importantly, JARID2-deficient embryos show lethal heart malformations similar to Ezh2 NK , including abnormally thin ventricular walls and ventricular septal defects, 16 which suggests that JARID2 together with PRC2 constitute core components of a regulatory network that controls chromatin structure during heart development. This view is also supported by the finding that JARID2 regulates Notch1 expression in the developing heart, probably by interacting with the methyltransferase SETDB1, which methylates H3K9. 17 Furthermore, JARID2 inhibits cardiomyocyte proliferation, 18 which raises the question of whether lack of EZH2 increases the levels of "free" JARID2, which, together with the increased concentration of Ink4a/b that was observed by He et al 6 
in Ezh2
NK mutants, might inhibit proliferation.
Finally, it is noteworthy that the PRC2 activity is dynamically regulated by different signaling cascades. 19, 20 For example, p38␣-mediated phosphorylation of EZH2 plays an important role in switching the balance at "bivalent" domains (marked by both repressive H3K27me3 and activating H3K4me3 histone modifications), often found in the chromatin of developmentally important genes. 20 Further insight into the signaling pathways, transcription factors, and epigenetic modifiers that control chromatin structure will lead to a better understanding of heart development and the pathogenesis of congenital heart defects, which still is only poorly understood.
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None. Figure. Proposed model of the role of the PRC2 complex in heart development. Factors expressed in cardiac progenitors (X, Y) recruit the PRC2-EZH2 complex to chromatin. EZH2 dimethylates and trimethylates H3K27, which leads to a chromatin conformation essential for later stages of heart development. Ezh2 deficiency derepresses gene expression, which leads to lethal heart defects. PRC2 function is also required at later developmental stages (in cardiomyocytes) to ensure proper cardiac growth, because Eed deficiency leads to hypoplasia of the myocardium. In cardiomyocytes, Ezh1 and Ezh2 appear to have redundant functions. VSD indicates ventricular septal defect; ASD, atrial septal defect.
